1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Vasundhara Rasayans Limited

Vasundhara Rasayans Limited

VRL.BO
Vasundhara Rasayans LimitedIN flagBombay Stock Exchange
170.20
INR
+0.20
- -
540.93MMarket Cap
Vasundhara Rasayans Limited
VRL.BO
(Bombay Stock Exchange)

Recent

price

170.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
58.64
65.63
58.31
48.26
48.6
52.22
62.2
66.97
71.36
84.17
119.38
115.67
107.18
- -
112.4
Revenue per Share
1.51
4.43
1.84
0.74
1.45
20.51
4.57
9.4
9.24
6.84
17.59
18.31
13.39
- -
18.34
Basic EPS, GAAP
4.08
8.44
-1.56
3.45
7.38
-33.68
0.91
0.72
-0.66
23.76
-20.71
13.12
-19.72
- -
- -
Free Cash Flow per Basic Share
0.58
0.58
0.58
0.6
- -
1.21
1.2
1.2
1.5
1.5
1
1.99
2
- -
- -
Dividend per Share
15.97
19.82
21.05
21.79
22.04
42.55
45.92
54.12
61.85
67.1
83.72
99.14
111.46
- -
10
Book Value per Share
16.64
20.49
21.72
22.46
22.71
43.22
46.59
54.78
62.52
67.76
84.39
99.81
112.13
- -
128.61
Tangible Book Value per Share
3
3
3
3
3
3
3
3
3
3
3
3
3
- -
3
Basic Weighted Avg Shares
186
209
185
153
154
166
198
213
227
268
379
370
340
357
357
Sales/Revenue/Turnover
8.02
13
6.24
5.04
7.26
9.14
6.51
13.32
13.48
7.82
14.3
16.66
10.84
15.01
15.01
Operating Margin (%)
9
9
5
6
6
3
- -
- -
1
1
1
3
4
4
4
Depreciation Expense
5
14
6
2
5
65
15
30
29
22
56
59
42
58
58
Net Income, GAAP
41.66
34.07
33.69
44.57
59.64
28
29.97
23.5
25.9
28.68
25.21
25.78
26.37
26.38
25.88
Effective Tax Rate (%)
2.58
6.75
3.15
1.54
2.99
39.28
7.35
14.04
12.94
8.12
14.74
15.83
12.49
16.21
16.32
Profit Margin (%)
14
21
9
7
11
135
148
173
108
204
258
303
335
387
387
Working Capital
23
14
12
4
- -
- -
- -
- -
- -
- -
- -
8
5
3
3
LT Debt
53
65
69
71
72
137
148
174
199
215
268
319
356
409
409
Total Equity
- -
15.7
6.55
3.31
3.71
6.73
4.45
10.51
9.77
6.36
14.96
13.9
7.31
9.49
9.55
Return on Invested Capital (%)
- -
16.11
7.91
2.52
5.51
52.92
9.84
18.68
16.21
10.42
21.55
18.63
12.14
27.33
27.51
Return on Capital (%)
- -
24.77
8.99
3.47
6.63
63.52
10.33
18.8
15.93
10.6
23.33
20.09
12.66
30.05
30.26
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
45
- -
15
LT Borrowings
9
- -
3
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
- -
3
Market Capitalization
568
538
336

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
455
- -
453
Cash, Cash Equivalents & STI
55
- -
50
Accounts Receivable, Net
37
- -
75
Inventories
26
- -
15
Total Current Liabilities
81
- -
66
Payables & Accruals
- -
- -
- -
ST Debt
45
- -
15
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.92%
15.65%
14.95%
Free Cash Flow
-515.33%
-879.34%
-69.91%
Net Income, GAAP
157.87%
28.99%
36.33%
Sales/Revenue/Turnover
9.58%
10.85%
5.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
83
93
82
111
370
2025
76
98
88
78
340
2026
76
88
74
119
357

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.01
4.37
4.35
- -
18.31
2025
2.71
4.61
4.57
1.43
13.39
2026
1.8
6.47
2.27
7.8
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.99
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
- -
Similar Companies
MatsukiyoCocokara & Co. (MSMKF)
Bio Green Med Solution, Inc. (BGMS)
LBX Pharmacy Chain Joint Stock Company (603883.SS)
H. Lundbeck A/S (HLUN-A.CO)
Damora Therapeutics, Inc. (GLTO)
Medical System Network Co., Ltd. (4350.T)
Business
Vasundhara Rasayans Limited is an Indian pharmaceutical ingredient manufacturer specializing in the production and export of antacid therapeutic active pharmaceutical ingredients (APIs). Founded in 1987 and headquartered in Hyderabad, the company operates manufacturing facilities in Mahad, Maharashtra, where it produces a broad range of antacid APIs including aluminum hydroxide gel, magnesium hydroxide, magaldrate, magnesium trisilicate, magnesium silicate, aluminum phosphate, and poly aluminum chloride. These products are offered in various forms such as paste, powder, and micronized grade powder, serving pharmaceutical, food, and chemical industries. The company also manufactures organic intermediates and dyes intermediates while providing technical backup support services. Additionally, Vasundhara produces products for non-pharmaceutical uses such as water treatment, lake color manufacture, construction chemicals, and cooking oil treatment. The company maintains manufacturing processes compliant with Good Manufacturing Practice (GMP) standards, including specialized facilities for Friedel-Crafts reaction and organic intermediate production with advanced contamination control systems like three-stage scrubbers and titanium cooling coil quenchers. Vasundhara Rasayans Limited's production capabilities emphasize environmental friendliness and quality assurance. The company serves both domestic and international markets, exporting its products globally. Recent major developments include the appointment of Shri Ashok Kumar Jain as an Additional Independent Director and Shri Kodakandla Sidarsanam as a Whole-time Director to strengthen corporate governance. In 2025, Vasundhara declared a Rs. 2 per share dividend reflecting operational continuity despite financial challenges indicated by a recent decline in stock price and profits. The company remains focused on expanding its product offerings and technical support while maintaining sustainable manufacturing practices. Vasundhara Rasayans Limited operates as a subsidiary of P&J Cretechem Private Limited and continues to innovate in antacid APIs and related chemical products. This description reflects the company’s comprehensive product portfolio, manufacturing sophistication, geographical presence in India with global export reach, and recent corporate governance enhancements and dividend announcement as of late 2025.